Cobra Biologics has unveiled plans to expand operations at its sites in the UK and Sweden to meet the increased demand of gene and immunotherapy companies to fast track their portfolios through to in-market supply. Over the next two years Cobra will invest up to approximately $19 million on a phased expansion plan, supporting the company’s R&D expertise in developing rapid and cost effective viral vector and DNA plasmid production platforms. The initial phase, will be in the UK and will e...